OZMOSI and Planview Partner to Integrate AI Planning in Pharma R&D

OZMOSI and Planview have announced a strategic partnership to connect structured clinical intelligence with AI portfolio planning in pharmaceutical research and development according to a press release.

The collaboration integrates OZMOSI's machine readable clinical datasets into Planview's AI portfolio planning platform, linking external scientific data with internal R&D operations. This connection allows pharmaceutical organizations to better predict market changes, prioritize investments, and make faster decisions based on standardized data.

OZMOSI provides structured intelligence from over 800,000 clinical trials, 35,000 drugs, and 4,000 diseases, consolidating data from regulatory filings, scientific literature, and company disclosures. Planview’s platform enables modeling of investment scenarios and alignment of initiatives with corporate strategy. Together, the companies aim to give pharmaceutical teams a unified view of the R&D landscape supported by AI analysis.

The integration is designed to enhance portfolio visibility by combining internal planning data with continuously updated external clinical insights, helping organizations evaluate competition, identify trends, and simulate outcomes more accurately.